The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Revolutionary technology will further boost OneSource’s scientific services offerings
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Subscribe To Our Newsletter & Stay Updated
